APA (7th ed.) Citation

EV, K., WC, W., LP, P., PPJ, P., NA, S., KE, B., . . . NV, N. (2025). Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes. Emerging infectious diseases, 31(3), 467. https://doi.org/10.3201/eid3103.241634

Chicago Style (17th ed.) Citation

EV, Kurbatova, et al. "Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes." Emerging Infectious Diseases 31, no. 3 (2025): 467. https://doi.org/10.3201/eid3103.241634.

MLA (9th ed.) Citation

EV, Kurbatova, et al. "Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes." Emerging Infectious Diseases, vol. 31, no. 3, 2025, p. 467, https://doi.org/10.3201/eid3103.241634.